Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
27
-
Total 13F shares, excl. options
-
3,036,722
-
Shares change
-
+1,169,107
-
Total reported value, excl. options
-
$3,885,911
-
Value change
-
+$107,658
-
Number of buys
-
18
-
Number of sells
-
-12
-
Price
-
$1.28
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q2 2024
38 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q2 2024.
Gain Therapeutics, Inc. - COM (GANX) has 27 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3,036,722 shares
.
Largest 10 shareholders include Timelo Investment Management Inc. (605,288 shares), DME Capital Management, LP (566,130 shares), Alyeska Investment Group, L.P. (450,000 shares), HOHIMER WEALTH MANAGEMENT, LLC (330,000 shares), GEODE CAPITAL MANAGEMENT, LLC (183,736 shares), VANGUARD GROUP INC (145,217 shares), Cable Car Capital LLC (145,000 shares), RENAISSANCE TECHNOLOGIES LLC (118,700 shares), CM Management, LLC (90,000 shares), and BlackRock Inc. (84,620 shares).
This table shows the top 27 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.